Sun, Jun
67 New Articles

B2RLaw and DZP Advise on Vinci HiTech Fund Investment into Oasis Diagnostics

B2RLaw and DZP Advise on Vinci HiTech Fund Investment into Oasis Diagnostics

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

B2RLaw has advised the Vinci HiTech ASI fund on its nearly PLN 14 million investment into Polish medical technology start-up Oasis Diagnostics. Domanski Zakrzewski Palinka advised Oasis Diagnostics.

Oasis Diagnostics has designed and developed a diagnostics system to detect pelvic-floor muscle injuries immediately after delivery. Their clinical-knowledge-based technology detects the problem in a one-minute procedure, according to B2RLaw.

"The nearly PLN 14 million investment raised will allow us to complete the product certification activities in the EU, initiate the certification procedure at the FDA, start production, and launch the product on the market in 2023," Oasis Board Member Edyta Hryniecka announced. "We also plan to conduct extensive clinical trials to confirm the benefits of implementing the early diagnosis of perinatal injuries with the ONIRY method into clinical practice."

"Our innovative system for detecting perinatal injuries, ONIRY, will soon allow us to perform a simple, painless, fast, and precise examination, assessing the condition of the pelvic floor muscles, in any woman who has just given birth by natural forces," Oasis CEO Katarzyna Borycka commented.

The B2RLaw team was led by Partner Agnieszka Hajos-Iwanska and included Counsels Malwina Niczke-Chmura and Paulina Wyrostek, Associate Konrad Czernecki, and Junior Associates Malgorzata Tomaka and Krzysztof Judasz.

The DZP team included Counsel Maciej Goszczyk and Senior Associates Maciej Zajda and Katarzyna Biarda.

Our Latest Issue